FCGR2B and melanoma: To determine whether B cell signature similar to the one observed in murine tumors and tolerant allografts is present in human cancers, we analyzed publicly available scRNAseq data from human melanoma samples34, focusing on the expression of FCGR2B and SIGLEC10 (the Siglec-G counterpart in humans) in the B cell compartment.